AI Validation in Regulated Environments

Start with intended use and consequence

The assurance question is not “is it AI?” but “what decision does this influence, and what happens if it is wrong?” An assistant that drafts a summary a qualified person reviews is a different risk profile from a model that classifies a deviation or releases a result.

There is no universal FDA requirement that applies to every AI application in regulated industry. Expectations depend on context of use, the applicable predicate regulations, and whether the output affects product quality, patient or user safety, or regulated records. Where a model is itself part of a medical device, an entirely different regulatory pathway applies.

Controls worth establishing now

• Documented intended use, scope of use and explicit out-of-scope statements
• Risk assessment covering incorrect, biased, unstable or fabricated output
• Data provenance, quality and representativeness for training and prompting
• Human oversight proportionate to consequence, with reviewer accountability
• Performance criteria, acceptance thresholds and test data sets
• Change management for model versions, prompts, parameters and retraining
• Ongoing monitoring for drift, degradation and unexpected behavior
• Supplier assessment for third-party models and hosted services
• Record integrity: what is retained, how it is attributable and how it is reviewed

Where AI meets computerized system assurance

Most GxP AI applications sit inside an existing computerized system boundary. The pragmatic path is to extend the assurance framework already in place — intended use, risk, proportionate testing, lifecycle control — rather than to invent a parallel program with different vocabulary.

Separate AI guidance scope from binding requirements

FDA's January 2025 AI-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations is draft guidance, not for implementation. FDA's separate January 2025 draft on AI supporting drug and biological product regulatory decisions proposes a context-of-use credibility framework. Neither document establishes a universal validation rule for every AI assistant used in a GxP business.

Classify the intended use first: a production/QMS function, an AI-enabled medical device function, or AI-generated evidence supporting a regulatory decision. Apply the relevant binding regulations and clearly distinguish recommendations, drafts and internal risk controls. Verify guidance status at the linked FDA sources before planning an engagement.

Build an assurance package for an AI-assisted workflow

Define the approved model/version, prompts, retrieval sources, user roles and human decision boundary. Use representative and challenging examples with predeclared acceptance criteria. For generative tools, assess incorrect citations, unsupported claims, missing context and sensitivity to input changes. A model's general benchmark score does not establish suitability for your quality decision.

• Retain controlled inputs, relevant outputs, source evidence and reviewer decisions
• Challenge fabricated answers, conflicting documents and malicious instructions in retrieved material
• Verify access controls and confidential-data handling with the supplier
• Define escalation, fallback and stop-use criteria for unacceptable output
• Assess model, prompt, retrieval-index and supplier changes; monitor performance and regressions